AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 13 - (NewsRx.com & NewsRx.net) -- ID Biomedical announced that Dr. Scott Halperin of the Clinical Trials Research Center at IWK Health Center and Dalhousie University in Halifax, Nova Scotia, presented phase I clinical trial results for the FluINsure flu vaccine at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego, California.
The FluINsure flu vaccine is the company's intranasally administered, nonliving vaccine for the prevention of influenza.
The clinical trial demonstrated that FluINsure, which is a trivalent product, was strongly immunogenic. Statistically-significant increases in both serum hemagglutination inhibiting (HAI) antibody and in virus-specific secretory immunoglobulin A (IgA) antibodies in the nose were shown for all three types of influenza viruses (A/H1N1, A/H3N2, and B) represented in the vaccine. Serum HAI antibody is an accepted correlate of immunity to influenza, and nasal secretory IgA antibody responses have received attention as an additional marker of disease resistance induced by live, attenuated nasal influenza vaccines.
In addition, FluINsure was well-tolerated by healthy adults in this randomized, double-blinded, and placebo-controlled trial. Only mild and short-lived runny nose was associated with the active vaccine when compared with placebo.
"Based on the results of this trial, the FluINsure flu vaccine appears to be quite competitive, in terms of both safety and immunogenicity, with other nasal flu vaccines," said Halperin.
"These are very encouraging results," said Dr. Louis Fries, ID Biomedical. "Across all subjects who got active vaccine, the average increase in serum HAI antibody levels to all three viruses was 3.2-fold. However, if you ...
Source: HighBeam Research, FluINsure vaccine results presented at ICAAC.(Interscience Conference...